Dr LeBel has served on Akesis’s board of directors since December 2007. The company also stated that current president, Jay Lichter will retain the position of CEO and add the title of chairman of the board of directors.
Dr LeBel has more than 18 years of experience as a biopharmaceutical industry executive, including 14 years at Amgen. Prior to joining Amgen, Dr LeBel held preclinical development positions at Arthur D Little and Alkermes.
Dr LeBel holds a BS in chemistry from the University of Detroit and a PhD in biomedical sciences/toxicology from Northeastern University.
Jay Lichter, president and CEO of Akesis, said: “The current level of company activity around our AKP-020 program for the treatment of Type 2 diabetes requires additional management resources, and we are very pleased that Carl LeBel will now be directly involved in the day-to-day progress of our research studies and trials, along with other business development initiatives.”